SEC Form 4	Ļ														
FO	RM 4	UNI	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549												
to Section 1	ox if no longer subject 5. Form 4 or Form 5 nay continue. <i>See</i> (b).	S	Filed p	<b>FOF CHANG</b> ursuant to Section 16 or Section 30(h) of th	6(a) of t	he Se	curities Excha	ange Act	t of 1934	ERSH	Est	B Number: mated average bu rs per response:	3235-0287		
1. Name and Address of Reporting Person <sup>*</sup> Arbuckle Stuart A				2. Issuer Name and Ticker or Trading Symbol <u>VERTEX PHARMACEUTICALS INC /</u> <u>MA</u> [ VRTX ]							tionship of Repor all applicable) Director Officer (give titl	e Other	Owner (specify		
(Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED				3. Date of Earliest Transaction (Month/Day/Year) 05/16/2022							below) EV	below P, COO	/)		
50 NORTHERN AVENUE				4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street) BOSTON MA 02210			0								X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(State)	(Zip)													
	•	Table I -	Non-Derivati	ve Securities A	cqui	ed, I	Disposed	of, or	Benefi	icially	Owned				
1. Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 ar			d 5)	5. Amount of Securities Beneficially Owned Followin Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	Amount	(A) or (D)	Price		Transaction(s) (Instr. 3 and 4)				

## Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

**S**<sup>(1)</sup>

**S**<sup>(1)</sup>

**S**<sup>(1)</sup>

**S**<sup>(1)</sup>

**S**<sup>(1)</sup>

**S**<sup>(1)</sup>

**S**<sup>(1)</sup>

11

10

20

32

10

10

40

D

D

D

D

D

D

D

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

## Explanation of Responses:

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock Common Stock

Common Stock

Common Stock

1. Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.

2. Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price.

3. Open market sales reported on this line occurred at a weighted average price of \$246.21 (range \$245.78 to \$246.25).

05/16/2022

05/16/2022

05/16/2022

05/16/2022

05/16/2022

05/16/2022

05/16/2022

4. Open market sales reported on this line occurred at a weighted average price of \$249.35 (range \$249.24 to \$249.45).

5. Open market sales reported on this line occurred at a weighted average price of \$250.78 (range \$250.35 to \$250.97).

6. Open market sales reported on this line occurred at a weighted average price of \$254.19 (range \$253.74 to \$254.57).

## Remarks:

## /s/ Sabrina Yohai, Attorney-in-05/18/2022 Fact

\*\* Signature of Reporting Person Date

\$246.21(2)(3)

\$247.95

\$249.35(2)(4)

\$250,78(2)(5)

\$251.43

\$252.66

\$254.19(2)(6)

64,882

64.872

64,852

64,820

64,810

64,800

64,760

140

D

D

D

D

D

D

D

Ι

401(k)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.